Literature DB >> 16941811

Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran.

Mehran Karimi1, Ameneh Sabzi, Flora Peyvandi, Pier Mannuccio Mannucci.   

Abstract

OBJECTIVE: The haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are rare disorders characterised by intravascular platelet aggregation and widespread thrombus formation in the microcirculation resulting in tissue ischaemia. A retrospective analysis was carried out in 136 patients with HUS or TTP hospitalized from April 1991 through March 2004 in three tertiary referral hospitals of Shiraz (the largest city in southern Iran) to evaluate the epidemiological aspects, clinical characteristics and laboratory findings of the two diseases.
METHODS: One hundred and one cases of HUS (49 females and 52 males) and 35 cases of TTP (21 females and 14 males) were identified. The mean age was 3.5 years for HUS, 30.8 years for TTP.
RESULTS: The mean annual incidence rate of HUS decreased approximately 30-fold throughout the observed period, while the incidence rate of TTP increased approximately 6-fold. A seasonal pattern was noted for both TTP and HUS, with the highest incidence during the summer months. Twenty patients with HUS and 16 patients with TTP died, resulting in case fatality rates of 19.8% and 45.7%, respectively. No prognostic factor was identified for TTP, whereas signs of neurological impairment and high leucocyte counts had an adverse effect on the prognosis of HUS patients.
CONCLUSIONS: This study shows that, in contrast to other countries, the incidence rate of HUS shows a decreasing trend in southern Iran, probably related to the prevention of gastrointestinal diarrhoeal infections (especially Escherichia coli 0157:H7) and to their improved management. The incidence of TTP is increasing in Iran as in other countries.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16941811     DOI: 10.1007/BF02934718

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  11 in total

1.  Changing epidemiology of the hemolytic uremic syndrome and thrombotic thrombocytopenic purpura in southern Iran.

Authors:  M Karimi; A Sabzi; F Peyvandi; P M Mannucci
Journal:  J Thromb Haemost       Date:  2006-03       Impact factor: 5.824

Review 2.  Thrombotic thrombocytopenic purpura: the systemic clumping "plague".

Authors:  Joel L Moake
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

Review 3.  Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.

Authors:  M Furlan; B Lämmle
Journal:  Best Pract Res Clin Haematol       Date:  2001-06       Impact factor: 3.020

4.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

5.  The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota.

Authors:  D L Martin; K L MacDonald; K E White; J T Soler; M T Osterholm
Journal:  N Engl J Med       Date:  1990-10-25       Impact factor: 91.245

6.  Population-based trends in pediatric hemolytic uremic syndrome in California, 1994-1999: substantial underreporting and public health implications.

Authors:  Kate C Cummings; Janet C Mohle-Boetani; S Benson Werner; Duc J Vugia
Journal:  Am J Epidemiol       Date:  2002-05-15       Impact factor: 4.897

7.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

8.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Authors:  M Furlan; R Robles; M Galbusera; G Remuzzi; P A Kyrle; B Brenner; M Krause; I Scharrer; V Aumann; U Mittler; M Solenthaler; B Lämmle
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

9.  Increasing mortality from thrombotic thrombocytopenic purpura in the United States--analysis of national mortality data, 1968-1991.

Authors:  T J Török; R C Holman; T L Chorba
Journal:  Am J Hematol       Date:  1995-10       Impact factor: 10.047

10.  Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome.

Authors:  David P Miller; James A Kaye; Kathleen Shea; Najat Ziyadeh; Clorinda Cali; Corri Black; Alexander M Walker
Journal:  Epidemiology       Date:  2004-03       Impact factor: 4.822

View more
  1 in total

1.  Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran.

Authors:  Francesco Rodeghiero
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.